FDA Approves Denileukin Diftitox-cxdl Immunotherapy for the Treatment of Adults With Relapsed or Refractory CTCL
The U.S. Food and Drug Administration (FDA) has approved denileukin diftitox-cxdl (Lymphir), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. Citius Pharmaceuticals’ Lymphir is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs. It is […]